0000899243-20-020691.txt : 20200729
0000899243-20-020691.hdr.sgml : 20200729
20200729214541
ACCESSION NUMBER: 0000899243-20-020691
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200729
DATE AS OF CHANGE: 20200729
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2018 GP LLC
CENTRAL INDEX KEY: 0001818701
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201058918
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9206
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2018 LLC
CENTRAL INDEX KEY: 0001818702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201058919
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9206
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM BioVentures 2014, L.P.
CENTRAL INDEX KEY: 0001609492
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39401
FILM NUMBER: 201058920
BUSINESS ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 425-9200
MAIL ADDRESS:
STREET 1: C/O MPM ASSET MANAGEMENT LLC
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iTeos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001808865
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-204-4583
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-28
0
0001808865
iTeos Therapeutics, Inc.
ITOS
0001609492
MPM BioVentures 2014, L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001818702
MPM BioVentures 2018 LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001818701
MPM BioVentures 2018 GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
2020-07-28
4
C
0
1269230
A
1269230
I
See Footnote
Common Stock
2020-07-28
4
C
0
84655
A
84655
I
See Footnote
Common Stock
2020-07-28
4
C
0
43687
A
43687
I
See Footnote
Common Stock
2020-07-28
4
C
0
801619
A
801619
I
See Footnote
Common Stock
2020-07-28
4
C
0
42605
A
42605
I
See Footnote
Common Stock
2020-07-28
4
C
0
15820
A
15820
I
See Footnote
Common Stock
2020-07-28
4
C
0
724702
A
1993932
I
See Footnote
Common Stock
2020-07-28
4
C
0
48336
A
132991
I
See Footnote
Common Stock
2020-07-28
4
C
0
24944
A
68381
I
See Footnote
Common Stock
2020-07-28
4
C
0
457706
A
1259325
I
See Footnote
Common Stock
2020-07-28
4
C
0
24326
A
66931
I
See Footnote
Common Stock
2020-07-28
4
C
0
9033
A
24853
I
See Footnote
Common Stock
2020-07-28
4
P
0
89955
19.00
A
2083887
I
See Footnote
Common Stock
2020-07-28
4
P
0
5994
19.00
A
138985
I
See Footnote
Common Stock
2020-07-28
4
P
0
3096
19.00
A
71727
I
See Footnote
Common Stock
2020-07-28
4
P
0
56814
19.00
A
1316139
I
See Footnote
Common Stock
2020-07-28
4
P
0
3020
19.00
A
69951
I
See Footnote
Common Stock
2020-07-28
4
P
0
1121
19.00
A
25974
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
3824591
D
Common Stock
1269230
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
255094
D
Common Stock
84655
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
131645
D
Common Stock
43687
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
2415530
D
Common Stock
801619
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
128384
D
Common Stock
42605
0
I
See Footnote
Series B Preferred Stock
2020-07-28
4
C
0
47674
D
Common Stock
15820
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
2361805
D
Common Stock
724702
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
157529
D
Common Stock
48336
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
81295
D
Common Stock
24944
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
1491666
D
Common Stock
457706
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
79281
D
Common Stock
24326
0
I
See Footnote
Series B-2 Preferred Stock
2020-07-28
4
C
0
29440
D
Common Stock
9033
0
I
See Footnote
Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 LP ("BV 2014") will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 (B) LP ("BV 2014(B)") will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 LP ("BV 2018") will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 (B) LP ("BV 2018(B)") will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014 will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014(B) will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018 will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018(B) will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("2014 BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of 2014 BV LLC and members of MPM Asset Management Investors BV2014 LLC.
MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("2018 BV LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). Luke Evnin, Ansbert Gadicke, Todd Foley and Edward Hurwitz are the managing directors of 2018 BV LLC and members of MPM Asset Management Investors BV2018 LLC.
Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
On July 28, 2020, BV 2014 purchased 89,955 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, BV 2014(B) purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, BV 2018 purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, BV 2018(B) purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
Form 2 of 2.
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC
2020-07-29
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC
2020-07-29